Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Duality Biotherapeutics, Inc. ( (HK:9606) ) has provided an update.
Duality Biotherapeutics, Inc., a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong, is preparing to issue renminbi-denominated shares for listing on the Sci-Tech Board in mainland China. The firm aims to broaden its capital base by accessing onshore Chinese investors, complementing its existing presence in Hong Kong’s equity market.
At an extraordinary general meeting held on April 29, 2026, shareholders overwhelmingly approved all eleven resolutions related to the planned RMB Share Issue. The approvals cover the specific mandate for the issue, use of proceeds, loss coverage plan, post-issue price stabilization and dividend return schemes, remedial measures for earnings dilution, governance procedures for meetings, and broad authorization for the board and management to execute the transaction.
Voting results showed near-unanimous support, with most resolutions receiving more than 99% of votes cast in favor, and the new rules of procedures for shareholders’ and board meetings passing with 100% support. This strong backing signals investor confidence in the company’s strategy to raise RMB funding and may strengthen its financial flexibility, corporate governance framework, and long-term positioning in both Hong Kong and mainland Chinese capital markets.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$383.47 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical sector. The company focuses on developing innovative therapeutics and accesses capital markets through multi-currency share structures, including proposed renminbi-denominated shares targeting mainland China’s Sci-Tech Board investors.
Its Hong Kong listing and planned RMB Share Issue position the firm to tap both international and domestic Chinese equity markets. This structure can enhance funding flexibility for R&D and commercialization, while subjecting the company to dual-market governance and disclosure standards that may influence its valuation and investor base.
Average Trading Volume: 835,339
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$25.4B
See more insights into 9606 stock on TipRanks’ Stock Analysis page.